ArticleThe journal of headache and pain2019
Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking.
Article in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- Emerging pharmacological targets in migraine therapy: CGRP and beyond.Frontiers in pharmacology · 2026Review
- Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors.British journal of pharmacology · 2024Article
- Mode and site of action of therapies targeting CGRP signaling.The journal of headache and pain · 2023Review
- CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.Physiological reviews · 2023Review
- Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.Journal of internal medicine · 2022Review
- Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.Cephalalgia : an international journal of headache · 2022Article
- The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice.Nature communications · 2022Article
- Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.Neurology and therapy · 2021Review
- Migraine therapeutics differentially modulate the CGRP pathway.Cephalalgia : an international journal of headache · 2021Article
- α-CGRP disrupts amylin fibrillization and regulates insulin secretion: implications on diabetes and migraine.Chemical science · 2021Article
- Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.Neurology · 2020Article
- Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors.ACS pharmacology & translational science · 2020Article
- Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache.Brain sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMonoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor are efficacious for the prevention of migraine headaches. The downstream molecular mechanisms following ligand-receptor blockade by which these antibodies prevent CGRP signaling through CGRP receptors have not been demonstrated.
methodsHere we produced tool monoclonal functional antagonist antibodies against CGRP and its canonical receptor and developed a novel cellular model using fluorogen-activated protein technology that allows detection of CGRP receptor internalization by flow cytometry and, for an extended time course, visualization by confocal microscopy.
resultsUsing this cell model we showed that these antagonist antibodies block both CGRP-induced cAMP signaling and CGRP receptor internalization. At least 10-fold higher concentrations of either antibody are necessary to block CGRP receptor internalization compared with cAMP accumulation in our cell model.
conclusionThese data reinforce our understanding of how monoclonal functional antagonist antibodies interfere with CGRP signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.